Latest Renal cell carcinoma Stories
Launch of Novel Immune Checkpoint Inhibitors Will Fuel Market Growth and Will Dramatically Enhance RCC Treatment Algorithm, According to Findings from Decision Resources Group BURLINGTON, Mass.,
VHL Alliance fundraiser dinner with New York Times bestselling author, Tom Rath, honors NCI and NIH reasearher, W.
- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER,
WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
MarketOptimizer.org adds “EpiCast Report Renal Cell Carcinoma - Epidemiology Forecast to 2023” to its store.
TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome
-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival
A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer.
- A person in a secondary role, specifically the second most important character (after the protagonist).